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Human immunodeficiency virus type 1 (HIV-1) can evade immunity shortly after transmission to a new host
but the clinical significance of this early viral adaptation in HIV infection is not clear. We present an analysis
of sequence variation from a longitudinal cohort study of HIV adaptation in 189 acute seroconverters followed
for up to 3 years. We measured the rates of variation within well-defined epitopes to determine associations
with the HLA-linked hazard of disease progression. We found early reversion across both the gag and pol genes,
with a 10-fold faster rate of escape in gag (2.2 versus 0.27 forward mutations/1,000 amino acid sites). For most
epitopes (23/34), variation in the HLA-matched and HLA-unmatched controls was similar. For a minority of
epitopes (8/34, and generally associated with HLA class I alleles that confer clinical benefit), new variants
appeared early and consistently over the first 3 years of infection. Reversion occurred early at a rate which was
HLA-dependent and correlated with the HLA class 1-associated relative hazard of disease progression and
death (P  0.0008), reinforcing the association between strong cytotoxic T-lymphocyte responses, viral fitness,
and disease status. These data provide a comprehensive overview of viral adaptation in the first 3 years of
infection. Our findings of HLA-dependent reversion suggest that costs are borne by some escape variants which
may benefit the host, a finding contrary to a simple immune evasion paradigm. These epitopes, which are both
strongly and frequently recognized, and for which escape involves a high cost to the virus, have the potential
to optimize vaccine design.
The dynamics of viral replication in acute and early human
immunodeficiency virus (HIV) infection are not well under-
stood as longitudinal data from large cohorts of seroconverters
are hard to assemble. Recent studies have shown that new HIV
infections may be the result of a single transmitted variant, that
new env gene mutations can be detected within a few weeks
(25), and that early immune escape can be detected at sites
across the HIV genome (9). These data add to a body of work
showing that cytotoxic T cells act early, contributing to the
early reduction in viremia (8, 30).
Whether early cytotoxic T-lymphocyte (CTL) immune re-
sponses influence longer-term clinical outcome is not clear.
Antigen-specific CTLs capable of producing gamma interferon
and other cytokines are detectable at all stages of HIV infec-
tion (1, 3, 24, 41). Much weight is placed on the macaque/
simian immunodeficiency virus model in which nearly total
peripheral blood CD8 T-cell elimination using monoclonal
antibodies results in rising viremia (42). The role of other
forms of host immunity (e.g., neutralizing antibodies, natural
killer cells, and macrophages) has, to some extent, been pur-
sued with less intensity in light of persuasive evidence that
CTLs can control retrovirus infection (46). The extent to which
the simian model mirrors HIV infection has been questioned
(5) and, despite exhaustive cellular assays of T-cell function—
from gamma interferon enzyme-linked immunospot assays(1,
27, 38) to polyfunctional cytokine matrices (2, 6)—no CTL
function correlates robustly with HIV plasma viral load or viral
dynamics. Moreover, analyses of evolutionary data suggest that
CTLs are inefficient at killing HIV-infected cells (4).
However, statistical analysis of data from large cross-sec-
tional studies link HLA class I alleles with specific genome-
wide HIV polymorphisms, suggestive of a pervasive selection
pressure enacted by CTLs (7, 10, 18, 36, 40). It is clear that
associations between some HLA class I alleles and particular
amino acid polymorphisms are robust although it is disputed
whether immune escape influences disease progression. The
viral fitness costs resulting from immune escape may even
contribute to better clinical outcomes associated with the pos-
session of HLA class I alleles such as B*27, B*57, and B*58
(18).
Evolutionary studies of HIV require longitudinal data from
large cohorts of patients sampled since seroconversion to de-
tect adaptation in new hosts as it accrues. HIV is one of the few
pathogens where it is possible to do this within individuals
because of the high viral turnover and rapid intrahost evolu-
tion. Here, we investigate a cohort of 189 acute seroconvert-
* Corresponding author. Mailing address: Department of Clinical
Medicine, Peter Medawar Building for Pathogen Research, South
Parks Road, Oxford OX1 3SY, United Kingdom. Phone: 44 01865
281230. Fax: 44 01865 281890. E-mail: rodney.phillips@ndm.ox.ac.uk.
 Published ahead of print on 19 November 2008.
1228
ers—the largest cohort reported to date—followed for up to 3
years to study the rates of viral mutation in individual epitopes
within internal HIV proteins and to determine the association
between HLA class I alleles and rates of immune escape and
reversion.
MATERIALS AND METHODS
Patients. From a cohort of 189 predominantly Caucasian male acute serocon-
verters recruited within a median of 60 days from the estimated date of sero-
conversion (interquartile range, 39 to 86 days), plasma samples were obtained at
the time of first presentation or trial enrollment (“baseline”) and then 6 months,
1 year, 2 years, and 3 years later. Patients were recruited from a prospective study
of acute HIV-1 infection at St. Mary’s Hospital, London, United Kingdom (as
fully described elsewhere [16]), and as part of randomized controlled trial of
short course therapy in acute HIV infection (SPARTAC [http://www.ctu.mrc.ac
.uk/studies/spartac.asp]). Criteria for acute HIV-1 infection were, as previously
described (17), a documented seronegative HIV-1 antibody test within the pre-
vious 6 months, acute symptomatic seroconversion illness, an evolving HIV-
specific antibody response as determined by enzyme-linked immunosorbent as-
say, and positive HIV-1 DNA PCR or positive HIV-1 RNA quantification
(Chiron 3.0; Chiron Inc., Emeryville, CA) in the absence of an antibody re-
sponse. In order to confirm primary HIV-1 infection, sequential serum samples
were later tested blindly with a “detuned” enzyme-linked immunosorbent assay
(data not shown).
We were unable to obtain baseline sequences on 15 pol and 16 gag genes. For
the pol gene, plasma samples were obtained and sequenced at baseline (n 174),
6 months (n  66), 1 year (n  111), 2 years (n  69), and 3 years (n  15) after
seroconversion. For the gag gene, from the same cohorts, plasma samples were
obtained and sequenced at baseline (n  173), 6 months (n  61), 1 year (n 
95), 2 years (n  62), and 3 years (n  30) after seroconversion. The majority
of patients were subtype B (164/189), confirmed using the REGA subtyping
tool (http://www.bioafrica.net/virus-genotype/html/index.html). The remainder,
which were excluded from this analysis, comprised subtypes A, A/G, C, and F.
Most patients recruited from the nonrandomized cohort study (n  88/101)
received a short (0.5 to 6 months; median, 3.0 months) course of highly active
antiretroviral therapy (HAART) at seroconversion but remained drug naïve until
either viral load, CD4 cell count, or clinical parameters were met to require
formal institution of HAART. For the SPARTAC trial, patients were random-
ized to receive no therapy or 12 weeks or 48 weeks of HAART and then to
remain off therapy according to clinical need.
Viral sequencing. Viral RNA was extracted from patient plasma (Qiagen Viral
RNA Extraction Kit), and the HIV-1 pol and gag genes were amplified in three
fragments using nested PCRs and primers described previously (19). The PCR
products were purified and sequenced using Big Dye dideoxy terminator chem-
istry (ABI).
Data analysis. Sequences were aligned and manually edited (Se-Al software
[www.evolve.zoo.ox.ac.uk]). Mixed residues containing more than one amino
acid were identified at a number of nucleotide positions within the raw sequence
data. In these cases the nucleotides were encoded as mixed if the secondary peak
reached 30% of the height of the primary peak. To determine the dynamics of
the amino acid changes, if at the subsequent time point the mixed site had
become homogeneous for one of the bases, this would be treated as the time at
which fixation had been reached. Clonal analysis of a selection of longitudinal
sequences was used to confirm the validity of using bulk sequences to identify the
times at which mutations either occur or revert and showed that predominant
homogeneity at the baseline time point was followed by accumulation of muta-
tions in line with the bulk sequences (data not shown).
For each patient, the baseline sequence was compared with HXB2, the Los
Alamos National Laboratory subtype B reference sequence, to identify any
mutants which might represent transmitted mutations or very early adaptation
(i.e., escape that had taken place prior to sampling). Subsequent sequences
collected in the first 3 years of infection were then compared with the patient’s
baseline sequence to determine the extent of intrahost evolution. As a quality
control measure, HXB2 and the population consensus sequence were compared.
The two sequences differed at four sites in Gag (p17, R76K and I94V; p24, I6L
and V83L) and five in Pol (protease, V3I, S37N, and L63P; reverse transcriptase
[RT], E122K and L214F). The affected epitopes in our analysis were
ELRSLYNTV (R76K; HLA B*0801) and VPLDEDFRKY (E122K; B*3501)
(mutated residues are in boldface), the latter being of interest as E122K has been
reported as a T-cell receptor escape mutation but was the consensus sequence in
our population.
For each amino acid in every patient, the timing of the emergence of poly-
morphisms was identified over 3 years for all amino acid positions (amino acids
1 to 417 for pol and amino acids 1 to 379 for gag). We defined a forward mutation
(FM) as a mutation away from the wild-type baseline (according to HXB2
sequence), whereas a backward mutation (BM), or reversion, was identified as a
mutation present in the baseline sequence which subsequently changed to the
HXB2 wild type. Although FM and BM are likely to represent immune escape
and reversion, respectively, in the absence of documented cellular immune re-
sponses for each patient, other causes of variation cannot be excluded, and these
generic terms are used. For FMs, the number of events at each time point was
compared with the number of baseline wild-type sites—i.e., the number with
potential to escape—and adjusted for 1,000 amino acid sites. For BM, the
denominator was the number of variant sites at baseline, representing sites with
the potential for reversion. Known optimal epitopes, defined from the LANL
database (www.lanl.com) were mapped onto the pol and gag gene sequences
(Table 1). Mutations within these epitopes were identified, and the rates of their
appearance were calculated.
HLA typing. Patients’ HLA types were determined to the oligo-allelic level
using Dynal RELITM reverse sequence-specific oligonucleotide kits for the
HLA-A, HLA-B, and HLA-C loci (Dynal Biotech). To obtain four-digit typing,
Dynal Biotech sequence-specific priming kits were used, in conjunction with the
Sequence-Specific Oligonucleotide type.
Relative hazards for disease progression. Hazards for disease progression
were obtained from previous data using Cox model analyses based on the Cau-
casian samples from four cohorts for which patients had known dates of sero-
conversion: the Multicenter AIDS Cohort Study, the Multicenter Hemophilia
Cohort Study, the San Francisco City Clinic Cohort, and AIDS Linked to Intra-
venous Experience (11, 21, 22, 37).
TABLE 1. Optimal epitopes used in the sequence analysis of the
seroconverter cohort
Epitope no. Referencea Optimal epitope HLArestriction
HXB2
position
(aa)b
Pol epitopes
1 GPKVKQWPL B*0801 RT 18–26
2 ALVEICTEMEK A*0301 RT 33–43
3 TVLDVGDAY B*3501 RT 107–115
4 15 VLDVGDAYFSV A*0201 RT 108–118
5 44 VPLDKDFRKY B*3501 RT 118–127
6 TAFTIPSI B*5101 RT 128–135
7 35 SPAIFQSSMT B*0702 RT 156–165
8 44 SPAIFQSSM B*3501 RT 156–164
9 AIFQSSMTK A*0301 RT 158–166
10 NPDIVIYQY B*3501 RT 175–183
11 VIYQYMDDL A*0201 RT 179–187
12 35 EELRQHLLRW B*44 RT 203–212
13 35 PIVLPEKDSW B*5701 RT 243–252
14 ILKEPVHGV A*0201 RT 309–317
Gag epitopes
1 21 KIRLRPGGKK B*27 p17 18–27
2 GGKKKYKLK B*0801 p17 24–32
3 KYKLKHIVW A*2402 p17 28–36
4 ELRSLYNTV B*0801 p17 74–82
5 SLYNTVATL A*0201 p17 77–85
6 TLYCVHQRI A*1101 p17 84–92
7 ISPRTLNAW B*5701 p24 15–23
8 SPRTLNAWV B*0702 p24 16–24
9 KAFSPEVIPMF B*5701 p24 30–40
10 TPQDLNTML B*0702 p24 48–56
11 39 GHQAAMQMLKE A*02 p24 61–71
12 TSTLQEQIGW B*5701 p24 108–117
13 47 PPIPVGEIY B*35 p24 122–130
14 45 GEIYKRWII B*0801 p24 127–135
15 KRWIILGLNK B*2705 p24 131–140
16 QASQEVKNW B*5701 p24 176–184
17 44 NANPDCKTI B*51 p24 193–201
18 DCKTILKAL B*0801 p24 197–205
19 ACQGVGGPGHK A*1101 p24 217–227
20 GPGHKARVL B*0702 p24 223–231
a All epitopes are derived from the Los Alamos National Laboratory A list of
optimal epitopes (http://www.hiv.lanl.gov/content/immunology/pdf/2008/optimal
_ctl_article.pdf), except for those indicated and referenced separately.
b aa, amino acids.
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Statistics. Fisher’s exact tests, unpaired t tests, and linear regression were used
in statistical analyses with Prism, version 4.0 (GraphPad Software).
RESULTS
Gene-specific rates of viral evolution following acute infec-
tion. The rates of FMs and BMs were compared in the gag and
pol genes. For FMs, which represent possible immune escape,
there was a difference between the two genes (P 0.001) up to
12 months (Fig. 1A). For pol, over the first 6 months the
prevalence was 0.27 FM/1,000 amino acid sites, and there was
a 10-fold greater prevalence of 2.2 FM/1,000 amino acid sites
in gag. Only after the first 12 months did the rate of escape in
pol approximate that in gag.
For both genes, mutations present at baseline reverted early.
For pol and gag, in the first 6 months, there were 26.2 rever-
sions/1,000 amino acid sites and 29.9 reversions/1,000 amino
acid sites, respectively. These rates were maintained for the
first 2 years of infection, illustrating that transmitted mutations
continued to revert (Fig. 1B). For a cohort of this size, it is not
feasible to obtain donor sequences, and so it is possible that not
all of these mutations were transmitted. Nevertheless, the changes
observed are consistently toward wild type, with little evidence of
recurrence of the mutations, suggesting that they were not origi-
nally selected, even if only temporarily, very early in infection.
As pol is also under selection pressure from antiretroviral
therapy, we identified amino acid sites (Stanford University
Drug Resistance Database [http://hivdb.stanford.edu/]) sus-
ceptible to drug resistance mutations. The proportion of both
reversion and putative escape polymorphisms that arose at
drug resistance residues was less than 5% of the new pol
FIG. 1. Prevalence of mutations in the HIV gag and pol genes in the first 3 years of infection. The prevalence of nonsynonymous mutations was
measured at baseline, 6 months, 1 year, 2 years, and 3 years following seroconversion in the gag and pol genes. The prevalence of FMs (a) and BMs
(b) were determined by coding when mutations at every amino acid either arose or reverted in each patient and normalizing these values per 1,000
amino acids (aa). Each data point is shown with 95% confidence intervals.
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mutations observed although baseline variants were identified
at M41 (four patients), T69 (five), A98 (three), K103 (five),
V108 (four), V118 (six), V179 (two), Y181 (one), M184 (one),
Y188 (one), L210 (three), and T215 (nine), the majority of
which persisted over time. These were randomly distributed
among HLA class I alleles, showing that the rates of observed
mutation within CTL epitopes were not biased by drug resis-
tance mutations. Although the median time between sampling
and the estimated date of seroconversion was 60 days (inter-
quartile range, 39 to 86), it is possible that the pol gene rate has
been underestimated due to very early escape missed by our
sampling. Although one might expect this bias to affect both
genes equally, in order to answer this question robustly, one
would need to analyze a cohort of acute and hyperacute pa-
tients identified within 4 weeks of infection.
Patterns of HLA-associated variation in HIV epitopes. To
determine how these patterns of forward mutation and rever-
sion related to immune pressure, we studied 34 well-defined
optimal epitopes restricted by HLA class I alleles (Table 1).
For these epitopes we had previously documented HLA-re-
stricted immune responses using gamma interferon enzyme-
linked immunospot assays in a cohort of chronically infected
patients (41). Epitope sequences were grouped according to
whether patients carried the requisite restricting HLA class I
allele. Any measure of variation needs to be controlled for
sequence variation when the site is not acting as an antigen,
i.e., in the absence of the restricting HLA class I allele. (Even
then, confounding effects such as overlapping epitopes may
occur). For each time point the proportion of wild-type
epitopes (those with the same sequence as the index peptide
from the Los Alamos National Laboratory HIV database [www
.hiv.lanl.gov]) was plotted for both the HLA-matched and un-
matched patients. A best-fit line was modeled to the data, the
initial rate of change in percentage of wild-type amino acids
(percentage points/year) was calculated, and the rates of
change in the HLA-matched and unmatched patients were
compared.
The rates of change were different among the 34 epitopes
(Fig. 2). Three common patterns of epitope variation emerged,
and these encompassed 31 of the 34 (91%) studied epitopes.
For the first group (n  16/34) the baseline sequences were
conserved (usually greater than 80% wild type) regardless of
whether the sequence was derived from the HLA-matched or
HLA-unmatched group, followed by only minimal change
(Fig. 2a). Such epitopes include KAFSPEVIPMF restricted
by HLA B*5701, ILKEPVHGV (A*0201), and VLDGDA
YFSV (A*0201). For the second group (n  7/34), the
epitopes are highly variable in both the HLA-matched and
-unmatched patients (mostly 30% wild-type at baseline) but,
again, with minimal change over time and no significant dif-
ference between the two (Fig. 2b). The examples shown are
SLYNTVATL (A*0201), EERLQHLLRW (B44), and GGKK
YKLK (B*0801). It is possible that there is so much back-
ground variation at these sites that we are not able to identify
small HLA-attributable changes. However, since HLA-
matched and HLA-unmatched patients are so similar, HLA
class I is unlikely to be the major source of variation within
these epitopes.
The third group (n  8/34) contained epitopes in which
there was a divergence between the proportion of wild-type
sequences in the HLA-matched and -unmatched patients over
time (Fig. 2c). The HLA-matched epitopes became increas-
ingly variant while baseline variation in unmatched epitopes
reverted toward wild-type sequences. This third group of
discordant epitopes included ISPRTLNAW (B*5701), KR
WILGLNK (B*2705), TAFTIPSI (B*5101), TLYCVHQRI
(A*1101), TSTLQEQIGW (B*5701), PIVLPEKDSW (B*5701),
and QASKEVKNW (B*5701). This third group is dominated
by epitopes restricted by HLA class I alleles which have pre-
viously been associated with lower viral loads (28), better clin-
ical outcomes (37), and a high prevalence of variation in
chronic infection (18). For some epitopes there were more
mutant sequences in the HLA-matched patients than in the
HLA-unmatched controls at baseline, which is suggestive of
early escape prior to first sampling. For example, the HLA
B*51-restricted epitope TAFTIPSI was mutant at the position
8 isoleucine in 10/13 patients at baseline compared with 68/151
B51-negative controls (P  0.021), and the B*57/58-restricted
TSTLQEQIGW was mutant at position 3 in 4/12 patients com-
pared with 12/135 controls (P  0.003). So, although the me-
dian interval between estimated seroconversion and first sam-
pling is 60 days, at certain epitopes escape had clearly already
taken place.
Epitopes restricted by beneficial HLA class I alleles show
greater variability over time than less favorable epitopes. We
plotted the initial rates of change for each epitope in the
presence and absence of HLA class I restriction (Fig. 3). By
intersecting the axes of the figure through (0, 0), four quad-
rants are defined. The inset figure shows the inferred behavior
of epitopes located in each section of the plot. Most epitopes
(20/34; 59%) are located on the left side of the y axis, suggest-
ing that these epitopes become increasingly variant over time
in the absence of HLA-associated pressure; i.e., there is ongo-
ing nonsynonymous change over time not necessarily attribut-
able to HLA class I-dictated immunity. We cannot rule out the
possibility that overlapping or undefined epitopes might con-
tribute to this. Twenty-three epitopes lie below the x axis,
showing that variants accumulate over time in the HLA-
matched patients. The less-variant epitopes lie close to the
intersection of the x and y axes, suggestive of weaker selection
pressure or structural constraint. Of interest are the epitopes
located in the lower right quadrant. In this quadrant are
epitopes that become more variable in the presence of HLA
but that revert once this pressure is removed. They include
KRWIILGLNK (restricted by HLA B*2705), ISPRTLNAW
(HLA B*5701), TSTLQEQIGW (HLA B*5701), QASKE
VKNW (HLA B*5701), and TLYCVHQRI (HLA A*1101).
The epitopes in the other three quadrants show little evidence
of HLA-specific selection.
To demonstrate how epitope variation unfolds over time, we
present key epitopes from Fig. 2 in a format that highlights the
differences between the rates of mutation. On these plots the
axes refer to the prevalence of variation within the cohort for
each epitope at each time point. The figures reveal the patterns
of epitope behavior through the movement of each epitope
around the plot over 3 years. Figure 4a shows examples of
neutral epitopes that remain close to the line x  y over time,
with no strong evidence of HLA-driven adaptation, and that
might represent the less effective “passenger” epitopes (29).
Figure 4b shows the protective or dynamic “driver” epitopes
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(29) evolving over time, with specific adaptation to the HLA
class I immune response. The figure includes the HLA B*5701-
restricted ISPRTLNAW, the B*2705-restricted KRWIILGLNK,
the B*5101-restricted TAFTIPSI, TSTLQEQIGW (B*5701),
and QASKEVKNW (B*5701). As well as moving down the
plot, these epitopes also move farther right over time. This
reveals new mutations in the HLA-matched patients combined
with reversion in the HLA-unmatched patients. This pattern is
not seen in Fig. 4a. Of interest in Fig. 4b is the plot for the
HLA B51-restricted TAFTIPSI. This is an epitope that is re-
stricted by a favorable HLA class I allele (37) and mutates
early (19) but is not associated with a fitness cost according to
this in vivo analysis. One might expect, therefore, mutations in
TAFTIPSI to accumulate in the population over time and to be
prevalent in populations with a high frequency of HLA B*51-
positive individuals.
HLA-associated rates of reversion, but not escape, correlate
with relative hazard of disease progression. Recent data sug-
gest that the frequencies with which epitopes are targeted by
CTLs correlates with both the rate of escape in early infection
(9) and the HLA-specific relative hazard of disease progression
(41). The rate at which epitopes acquire new variation in early
infection has not been directly compared with the risk of dis-
ease progression. In the absence of virological or clinical out-
come data from the SPARTAC cohort, which remains blinded,
the well-described relative hazards obtained from large West-
ern seroconverter cohorts were used (11, 21, 22, 37). We cor-
related the rate of variation for each epitope in the absence
and presence of the restricting HLA class I allele with the
documented relative hazards for disease progression for spe-
cific HLA class I alleles for the time to reach a CD4 cell count
of less than 200 cells/l, time to AIDS using the CDC 1987
FIG. 2. Prevalence of variation within defined optimal epitopes in HLA-matched and HLA-unmatched patients. For the epitopes shown, the
percentage of those with wild-type sequences is shown for each time point. Each epitope is analyzed according to whether patients carried the
restricting HLA class I allele (blue for HLA-unmatched and red for HLA-matched epitopes). Best-fit lines are drawn through the points using
linear regression. Error bars show the 95% confidence intervals for each time point. Epitopes are divided into three groups and shown with an
illustrative model: those that are conserved at baseline and over time regardless of HLA matching (a), those that are variant at baseline and over
time (b), and those that are conserved at baseline but become more variable over time in the HLA-matched patients only (c). P values represent
whether there is a statistically significant difference in the slopes of the two datasets.
FIG. 3. Rates of mutation in the first 3 years of infection in HLA-matched and HLA-unmatched epitopes. Each epitope is plotted according
to its rate of change (percent change in wild type/year) in HLA-matched and -unmatched patients. The insert shows the implications of a data point
lying in each of the four quadrants. Each epitope can be identified using the key. HLA-ve, HLA negative; HLAve, HLA positive; WT, wild type;
MT, mutation/mutant.
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FIG. 4. The evolution of epitopes over time. The figure shows the transit of neutral (a) and dynamic (b) epitopes across the plot over time. Each
epitope is plotted at each time point according to the relative prevalence of wild-type (WT) sequences in HLA-matched (y axis) and unmatched
(x axis) patients. The epitopes shown in panel a are KYKLKHIVW, restricted by A*2402 (A24); SLYNTVATL, A*0201 (A2); ALVEICTEMEK
A*0301 (A3); and GPKVKQWPL, B*0801 (B8). The epitopes shown in panel b are TAFTIPSI, restricted by B*5101 (B51); ISPRTLNAW, B*5701
(B57); KRWIILGLNK, B*2705 (B27); QASKEVKNW, B*5701 (B57); and TSTLQEQIGW, B*5701 (B57).
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definition (time to AIDS 1987) (12), time to AIDS using the
CDC 1993 definition (time to AIDS 1993) (13), and time to
death. As previously described, the population HLA frequen-
cies in these cohorts and our United Kingdom patients are
strongly correlated (41).
There was no correlation between the rates of epitope
mutation in the presence of their restricting HLA class I
alleles and the associated relative hazards of disease pro-
gression (CD4 of 200, P  0.08 and R2  0.09; time to
AIDS 1987, P  0.16 and R2  0.06; time to AIDS 1993, P 
0.09 and R2  0.09; death, P  0.18 and R2  0.06) (data not
shown). However, when a variant epitope is transmitted to
an HLA-mismatched patient, the rate at which the epitope
reverts (percent wild type/year) is strongly associated with
the relative hazard for the restricting HLA class I allele (Fig.
5a to d). Measuring the epitope variation rate in an HLA-
unmatched patient is effectively an in vivo fitness assay. The
statistical correlation of reversion rates with the parameters
for HLA-associated relative hazard is strong evidence that
viral escape from beneficial HLA class I alleles results in
strong fitness costs in the epitopes that they restrict.
DISCUSSION
We present a study of a large cohort of serially sampled
HIV-infected seroconverters, with data analyzed for up to 3
years after infection. There are three main findings. First, the
rates of FM in the two study genes vary, with escape mutations
being more common in the more immunogenic gag gene al-
though in both genes there is rapid and early reversion of
transmitted mutants. Second, the patterns of variation are
driven by changes within epitopes, with the most variant being
restricted by beneficial HLA class I alleles. Third, we show a
correlation between the HLA class I-associated hazard and
the rate of reversion in HLA-unmatched epitopes, providing
strong evidence for a role of viral fitness in the benefit
conferred by certain HLA class I alleles.
In both the gag and pol genes, reversion occurred early—
generally within the first year of infection—whereas FMs arose
faster in the gag gene. There may be a number of explanations
for this. In new hosts, the controlling effect of the previous
donor’s immune response on HIV variability has been relaxed
before the new recipient has mounted his own T-cell response.
Accordingly, an initial limiting factor to viral replication will be
the fitness cost of the transmitted mutations. If one assumes
that HIV can produce extensive de novo variants early in
infection, then one might expect the most costly escape muta-
tions to revert quickly and early. Our data agree with the
findings of Li et al., who reported early reversion on clonal
analysis of seven acute seroconverters, also predominantly
within 6 months (32). These data are in contrast to the trans-
mission of drug resistance mutations to drug-naïve hosts. Here,
FIG. 5. Linear regression analysis of relative hazard of disease progression against rates of mutation within epitopes in HLA-unmatched
subjects. Linear regression analysis of the rate of change of individual epitopes in HLA-unmatched patients (percent wild type/year) against the
relative hazard of disease progression for the restricting HLA class I allele for time to a CD4 cell count of 200 cells/l (a), time to AIDS 1987
(b), time to AIDS 1993 (c), and time to death (d). A negative mutation rate indicates mutation away from wild type and a positive mutation rate
indicates change toward wild type (reversion).
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it would appear that transmitted variants—mostly in pol—are
maintained, often for a number of years (20). Why should
there be a different dynamic for the transmission of immune
escape and drug resistance mutations? Possibilities include the
different potencies of the selection pressures driving variation,
the role of compensatory mutations, and the pathways for
reversion. For certain antiretroviral agents including nucleo-
side reverse transcriptase inhibitors and protease inhibitors, a
number of mutations cluster together to confer the reduction
in drug susceptibility, some of which require two nucleotide
mutations within the same codon. It is feasible, therefore, that
the reversion pathways for these drug resistance mutations
require much greater kinetics on behalf of the virus and are
more likely to persist once transmitted.
We found that escape occurs more quickly in the gag gene.
This is not surprising as Gag has consistently been reported as
one of the main targets of the immune response in acute
infection, and the early detection of escape reflects this. In
addition, the enzymatic function of Pol may impose greater
sequence conservation than the structural Gag protein. It is
possible that we have underestimated the rate of escape in pol
as in some patients escape mutations may have occurred prior
to sampling; however, data from Brumme et al. (9) also reveals
a similar discrepancy in gag and pol.
We find that, in early infection, the variation appears most
rapidly within epitopes restricted by HLA class I alleles that
have been associated with lower viral loads and delayed pro-
gression. In particular HLA B*2705, B*5101, and B*5701 were
associated with faster rates of mutation, but this was not the
case for all the epitopes restricted by these alleles. A key
finding from this study is the correlation between the rates of
reversion of transmitted mutations and the relative hazard of
disease progression reported for the alleles that select them.
The rate of reversion for a transmitted mutation, when assayed
across a large number of patients, is an in vivo measure of its
associated fitness cost. Accordingly, our data reflect the corre-
lation between HLA class I alleles that are linked with a de-
layed progression to AIDS and the fitness costs incurred by the
virus due to the strong selection pressures these alleles impose.
We cannot comment on whether transmission of an escape
variant to an HLA-mismatched recipient is of clinical advan-
tage or disadvantage. This is a separate analysis that will be
undertaken once the SPARTAC trial has been unblinded.
Recently, the clinical significance of reverting sites and their
association with lower viral loads have been inferred from
cross-sectional data from chronically infected patients (34).
Although we agree with the findings of that study, to comment
on reversion requires longitudinal analysis of acutely infected
patients, ideally, although not necessarily, with viral sequence
data from the donor. Cross-sectional analyses from chronic
infection make assumptions on the nature and frequency of
mutation transmission. Although our study is a longitudinal
analysis of acutely infected patients, we do not know the se-
quence of the donor virus for the members of our cohort. How
might this bias our results? In the analysis, we identified any
variant epitope present in the baseline sample, i.e., the sample
taken at first clinical presentation within a median of 60 days of
the estimated date of seroconversion. Variation was defined
against the sequence of the wild-type optimal epitope in the
Los Alamos National Laboratory HIV database (www.lanl
.gov). If the variant remained unchanged over time, this was
classified as a nonrevertant. There are two potential sources of
error that arise in the absence of the donor sequence. First,
rather than being transmitted the variant may have risen anew
in the recipient, reflecting adaptation to the new selective
environment. If such a variant changed to a wild-type genotype
at a later time point, then this would suggest a transient
escape, a process which we encountered rarely in our cohort
(0.15% of all amino acids) (data not shown). Accordingly, a
change from a variant to wild-type sequence is likely to
reflect true reversion. Alternatively, if the variant persisted,
this could reflect a nonreverting transmitted mutation or a
stable new mutation in the new host. Without the donor
sequence it is impossible to distinguish between these two
outcomes. However, when the reverting mutation is a well-
documented escape mutation in a patient who does not carry
the restricting HLA class I allele, this additional information
supports the argument that this is true reversion. We also
cannot exclude the influence of overlapping epitopes with
escape mutations at the same amino acid sites.
Our data are intriguing since some escape is evident, but for
most epitopes (23/34) there is no significant difference in the
rates of variation in the HLA-matched and HLA-unmatched
patients. If one assumes that HIV can respond to selection
pressure by accepting mutations with fitness costs (26), the lack
of variation in so many epitopes suggests weak selection rather
than structural constraint and, by inference, a weak CTL im-
mune response. Alternatively, these epitopes may simply be
critical sites of conservation within the HIV genome. If they
are conserved, then CTLs should have a “good” antigen to
target. If no escape is detected yet variation is tolerated, it
follows that the CTLs are weak, which is compatible with
recent mathematical models (4, 5). Cellular assays of the CTL
immune response are currently being undertaken on the sero-
converter cohort to resolve this issue. The results of these
studies in combination with the sequence variation data will
inform vaccine design by highlighting epitopes that are both
strongly and frequently recognized and for which escape in-
volves high cost to the virus. However, the observation that
variation and immune escape are limited to a few epitopes
associated with slower disease progression is compatible with
data from African and European cohorts of chronically in-
fected patients (18).
The evidence that immune escape is the precursor to a rise
in viral load and clinical progression is limited (14, 23). We
have previously argued that the fitness cost imposed by certain
immune escape mutations may be one of a number of factors
which benefit the host (18). These hypotheses have been borne
out by in vitro fitness assays (33). Since escape polymorphisms
occur in patients with protective HLA class I alleles, one has to
conclude that the selection pressure imposed by CTLs dictated
by these alleles is so strong that it is still to the virus’s advan-
tage to escape, despite the fitness cost. Hence, there is rapid
reversion of these mutations once they are transmitted to an
environment where they are no longer beneficial. Some muta-
tions do not appear to carry a fitness cost (e.g., the HLA
B51-restricted TAFTIPSI), and mutants are therefore likely to
accrue over time, possibly rising to fixation and so becoming
the consensus sequence (31). Should our analysis include
epitopes that already contain an escape variant as part of the
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consensus sequence (“negatopes”), this would present as ap-
parent reversions in HLA-matched hosts and a slow rate of
“escape” in HLA-mismatched hosts. Such events were ex-
tremely rare in this cohort (data not shown), and although
negatopes have been described within the genome (31), we do
not feel that they bias this analysis.
Our cohort is part of a clinical trial, so a majority of patients
received a short course of antiretroviral therapy (ART) at
seroconversion. Could our findings have been influenced by a
short course of drug therapy? The reduction in viral load,
replication, antigenic load, and the predictable decline in CTL
immune responses that might be expected from a short course
of ART would be expected to slow down viral evolution and
immune escape and decrease genetic diversity. Our data show
that mutations that could reflect both escape and reversion are
present within 6 months, and in a number of epitopes (e.g., the
pol epitope TAFTIPSI), the escape variants had already
reached fixation on clonal analysis (data not shown). In addi-
tion, as therapy will be distributed randomly across the differ-
ent HLA class I alleles, any difference in viral variation attrib-
uted to different HLA class I alleles should not be significantly
biased. Evidence from unpublished data from a similar sero-
converter cohort (Stephane Hue, personal communication)
suggests that the impact on genetic diversity of a short course
of HAART at seroconversion is limited although this needs to
be formally assessed in a controlled trial. The epitopes that we
have shown to mutate, do so quickly although it is possible
that, if anything, we have underestimated this. Most other
epitopes do very little; if there is a differential impact of a short
course of ART on epitope variability, this warrants further
analysis once the SPARTAC trial is unblinded.
Our results support the notion that HIV adaptation to new
hosts begins quickly following transmission but also show that
this process continues for at least 36 months, predominantly at
a few key immunogenic epitopes. In addition, the differential
rates of reversion according to associated clinical hazard is
strong evidence that immune escape from “protective” HLA
class I alleles comes at a cost to the virus. Further work is
needed to determine why many epitope sequences are con-
served. If fitness cost, rather than a weak selection pressure, is
the key, then these will be epitopes worth targeting for vaccine
design.
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